SCHEMBL14320820

SCHEMBL14320820

COC(=O)c1cccc(-c2nc(Nc3ccc4c(c3)NC(=O)CC4)c3[nH]ncc3n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 2/20 0.48
PDE5A O76074 2/20 0.46
ABCG2 Q9UNQ0 3/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
ABCB1 P08183 1/20 0.41
ROCK2 O75116 2/20 0.40
SYK P43405 4/20 0.39
JAK2 O60674 2/20 0.39
ABCC1 P33527 1/20 0.39
PDGFRB P09619 1/20 0.39
PIK3CA P42336 1/20 0.39
ULK1 O75385 2/20 0.39
BUB1 O43683 1/20 0.38
ALOX15 P16050 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320504 0.95 PDE5A (0.44) CRBNPDE5AABCG2KDM4EMAPT
SCHEMBL14320571 0.92 CRBN (0.54) CRBNPDE5AABCG2KDM4EMAPT
SCHEMBL14320319 0.92 MEN1 (0.43) CRBNPDE5AABCG2ROCK2SYK
SCHEMBL14320613 0.87 BTK (0.42) ABCG2ROCK2SYKJAK2KIF11
SCHEMBL14320404 0.86 LMNA (0.52) CRBNPDE5AABCG2KDM4EMAPT
SCHEMBL14320889 0.86 SYK (0.46) PDE5AABCG2KDM4EMAPTABCB1
SCHEMBL14320794 0.86 ALDH1A1 (0.42) ABCG2ROCK2SYKJAK2ABCC1
SCHEMBL14320604 0.85 ULK1 (0.44) KDM4EMAPTROCK2SYKPIK3CA
SCHEMBL14320521 0.85 CYP1A2 (0.48) KDM4EMAPTALOX15HSD17B10LMNA
SCHEMBL14320898 0.84 SYK (0.46) CRBNABCG2ABCB1SYKJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
CN-103492389-A Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors ORIGENIS GMBH 2014-01-01 CN claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
CN-103492389-A Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors ORIGENIS GMBH 2014-01-01 CN disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK CRBN 1989/4885PDE5A 1895/4885ABCG2 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.